Bachem Holding AG, Bachem stock

Bachem stock reports CHF 326.4 million first-half sales

Published on 09/29/2026 at 18:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem Holding AG reported CHF 326.4 million in first-half 2026 sales. The company plans more than CHF 500 million for a Sisslerfeld facility, with production expected to begin in 2030.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund
Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem Holding AG reported sales of CHF 326.4 million for the first half of 2026, up 4.3 percent from the prior-year period. In local currencies, sales increased 7.3 percent, according to the company's half-year report.

Profitability affected by growth costs

Operating income before depreciation and amortization, or EBITDA, declined 9.0 percent to CHF 82.8 million, while the EBITDA margin fell to 25.4 percent from 29.1 percent in the first half of 2025. Net income increased 0.3 percent to CHF 50.3 million. Bachem expects 2026 sales growth of 35 percent to 40 percent in local currencies and an EBITDA margin in the low thirties, the report said.

Sisslerfeld investment planned

In an ad hoc announcement dated July 21, 2026, Bachem said it plans to invest more than CHF 500 million in a large-scale production facility at Sisslerfeld in Eiken, Switzerland. The company expects commercial production at the site to begin in 2030. The project is part of a strategic collaboration tied to an agreement to supply large volumes of peptides, according to Bachem's announcement.

Disclaimer...

en | boerse | 70199788 |